Beam Therapeutics Inc
BEAM
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Beam Therapeutics is a biotechnology company whose core business model involves the commercial exploitation of animals for research and development. The company’s precision gene editing platform and product pipeline, including candidates like BEAM-301 for liver disease, rely on preclinical testing in animal models to advance therapeutic candidates. This use of animals is central to its operations, as the company’s exclusive license agreements in the field of gene editing are structured around the development and exploitation of licensed products that necessitate animal data.
While the specific scale of Beam’s animal use is not publicly quantified in routine disclosures, the company’s foundational license agreements and regulatory filings confirm that animal testing is an inherent and non-incidental part of its business. The exploitation of animals for biomedical research falls under this broad exclusion category, as the activity is commercial in nature and integral to the company’s mission of developing and commercializing gene editing therapies.
Beam Therapeutics is a preclinical-stage biotechnology company whose core platform technology, base editing, requires animal testing as part of its therapeutic development process. The company’s SEC filings consistently list “animal studies” as a standard component of its preclinical research and regulatory pathway for its investigational gene therapies. As a company developing novel genetic medicines, Beam’s research and development activities inherently involve animal testing to assess safety, efficacy, and biodistribution of its drug candidates, as required by the U.S. Food and Drug Administration for clinical trial authorization. This places the company within the scope of the animal testing exclusion for its direct and necessary use of animals in product development.
Research Sources
5 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.